A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).

ABSTRACT:

Objectives

To determine the efficacy and tolerability of sunitinib in recurrent or persistent clear cell ovarian cancer patients.

Methods

All patients had one or two prior regimens with measurable disease. Tumors were at least 50% clear cell histomorphology and negative for WT-1 antigen and estrogen receptor expression by immunohistochemistry. Sunitinib 50 mg per day for 4 weeks was administered in repeated 6-week cycles until disease progression or prohibitive toxicity. Primary end points were progression-free survival (PFS) at 6 months and clinical response. The study was designed to determine if the drug had a response rate of at least 20% or 6-month PFS of at least 25%.

Results

Of 35 patients enrolled, 30 were treated and eligible (median age: 51, range: 27-73). T

SUBMITTER: Chan JK 

PROVIDER: S-EPMC6235144 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature